Skip to main content
Erschienen in:

17.01.2023 | main topic

Anticonvulsive treatment in autoimmune encephalitis: a systematic literature review

verfasst von: Judith N. Wagner, MD, MHBA

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 1-2/2024

Einloggen, um Zugang zu erhalten

Summary

Background

Epileptic seizures are a common manifestation of autoimmune encephalitis (AIE). Immunosuppression (IT) is an efficient therapeutic approach, particularly in AIE associated with antibodies against extracellular structures. The role of antiseizure medication (ASM) is less clear. However, it may be beneficial in disease refractory to IT or in chronic post-AIE epilepsy.

Methods

We conducted a systematic review assessing the PubMed and Cochrane databases to identify all reports on patients with epileptic seizures due to AIE in whom ASM was used and report it according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards. We included case series (minimum 3 eligible patients), retrospective and prospective observational studies, and randomized controlled trials. The main outcome assessed was therapeutic efficacy of ASM. Secondary outcomes comprise number, type, and adverse effects of ASM. Descriptive statistics were used. The level of evidence was assessed according to the Centre for Evidence-Based Medicine.

Results

We screened a total of 3371 studies and included 30 (7 prospective, 23 retrospective). The reports cover a total of 708 patients, the majority (72.5%) suffering from AIE with antibodies against extracellular structures. Type of AIE, seizure frequency, and number and type of ASM used were heterogenous. While most patients profited from IT and/or ASM, the effect of ASM could rarely be isolated. Nine studies report on patients who received ASM monotherapy or were on ASM for a relevant length of time before IT initiation or after IT failure. One study reports a significant association between seizure freedom and use of sodium channel inhibitors. However, levels of evidence were generally low.

Conclusion

Few robust data exist on the particular efficacy of ASM in autoimmune epileptic seizures. While these patients generally seem to respond less well to ASM or surgical interventions, sodium channel blockers may have an additional benefit compared to other substances. However, levels of evidence are low and early IT remains the mainstay of AIE therapy. Future trials should address optimal ASM selection and dosing in AIE.
Literatur
1.
2.
3.
Zurück zum Zitat Shen C‑H, Fang G‑L, Yang F, Cai M‑T, Zheng Y, Fang W, et al. Seizures and risk of epilepsy in anti-NMDAR, anti-LGI1, and anti-GABAB R encephalitis. Ann Clin Transl Neurol. 2020;7:1392–9.CrossRefPubMedPubMedCentral Shen C‑H, Fang G‑L, Yang F, Cai M‑T, Zheng Y, Fang W, et al. Seizures and risk of epilepsy in anti-NMDAR, anti-LGI1, and anti-GABAB R encephalitis. Ann Clin Transl Neurol. 2020;7:1392–9.CrossRefPubMedPubMedCentral
4.
5.
Zurück zum Zitat Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018;141:348–56.CrossRefPubMed Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018;141:348–56.CrossRefPubMed
6.
Zurück zum Zitat Sulentic V, Petelin Gadze Z, Derke F, Santini M, Bazadona D, Nankovic S. The effect of delayed anti-NMDAR encephalitis recognition on disease outcome. J Neurovirol. 2018;24:638–41.CrossRefPubMed Sulentic V, Petelin Gadze Z, Derke F, Santini M, Bazadona D, Nankovic S. The effect of delayed anti-NMDAR encephalitis recognition on disease outcome. J Neurovirol. 2018;24:638–41.CrossRefPubMed
7.
Zurück zum Zitat Dubey D, Britton J, McKeon A, Gadoth A, Zekeridou A, Lopez Chiriboga SA, et al. Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy. Ann Neurol. 2020;87:313–23.CrossRefPubMed Dubey D, Britton J, McKeon A, Gadoth A, Zekeridou A, Lopez Chiriboga SA, et al. Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy. Ann Neurol. 2020;87:313–23.CrossRefPubMed
8.
Zurück zum Zitat Feyissa AM, López Chiriboga AS, Britton JW. Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm. 2017;4:e353.CrossRefPubMedPubMedCentral Feyissa AM, López Chiriboga AS, Britton JW. Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm. 2017;4:e353.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Cabezudo-García P, Mena-Vázquez N, Villagrán-García M, Serrano-Castro PJ. Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review. Seizure. 2018;59:72–6.CrossRefPubMed Cabezudo-García P, Mena-Vázquez N, Villagrán-García M, Serrano-Castro PJ. Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review. Seizure. 2018;59:72–6.CrossRefPubMed
10.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.CrossRefPubMedPubMedCentral Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128:305–10.CrossRefPubMedPubMedCentral Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128:305–10.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Mäkelä K‑M, Hietaharju A, Brander A, Peltola J. Clinical management of epilepsy with glutamic acid decarboxylase antibody positivity: The interplay between immunotherapy and anti-epileptic drugs. Front Neurol. 2018;9:579.CrossRefPubMedPubMedCentral Mäkelä K‑M, Hietaharju A, Brander A, Peltola J. Clinical management of epilepsy with glutamic acid decarboxylase antibody positivity: The interplay between immunotherapy and anti-epileptic drugs. Front Neurol. 2018;9:579.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat O’Connor K, Waters P, Komorowski L, Zekeridou A, Guo C‑Y, Mgbachi VC, et al. GABAA receptor autoimmunity: A multicenter experience. Neurol Neuroimmunol Neuroinflamm. 2019;6:e552.CrossRefPubMedPubMedCentral O’Connor K, Waters P, Komorowski L, Zekeridou A, Guo C‑Y, Mgbachi VC, et al. GABAA receptor autoimmunity: A multicenter experience. Neurol Neuroimmunol Neuroinflamm. 2019;6:e552.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Kurukumbi M, Dave RH, Castillo J, Shah T, Lau J. Rituximab for autoimmune encephalitis with epilepsy. Case Rep Neurol Med. 2020;2020:5843089.PubMedPubMedCentral Kurukumbi M, Dave RH, Castillo J, Shah T, Lau J. Rituximab for autoimmune encephalitis with epilepsy. Case Rep Neurol Med. 2020;2020:5843089.PubMedPubMedCentral
15.
Zurück zum Zitat von Rhein B, Wagner J, Widman G, Malter MP, Elger CE, Helmstaedter C. Suspected antibody negative autoimmune limbic encephalitis: outcome of immunotherapy. Acta Neurol Scand. 2017;135:134–41.CrossRefPubMed von Rhein B, Wagner J, Widman G, Malter MP, Elger CE, Helmstaedter C. Suspected antibody negative autoimmune limbic encephalitis: outcome of immunotherapy. Acta Neurol Scand. 2017;135:134–41.CrossRefPubMed
16.
Zurück zum Zitat Dubey D, Samudra N, Gupta P, Agostini M, Ding K, Van Ness PC, et al. Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy. Seizure. 2015;29:143–7.CrossRefPubMed Dubey D, Samudra N, Gupta P, Agostini M, Ding K, Van Ness PC, et al. Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy. Seizure. 2015;29:143–7.CrossRefPubMed
17.
Zurück zum Zitat Dubey D, Konikkara J, Modur PN, Agostini M, Gupta P, Shu F, et al. Effectiveness of multimodality treatment for autoimmune limbic epilepsy. Epileptic Disord. 2014;16:494–9.CrossRefPubMed Dubey D, Konikkara J, Modur PN, Agostini M, Gupta P, Shu F, et al. Effectiveness of multimodality treatment for autoimmune limbic epilepsy. Epileptic Disord. 2014;16:494–9.CrossRefPubMed
18.
Zurück zum Zitat Gozubatik-Celik G, Ozkara C, Ulusoy C, Gunduz A, Delil S, Yeni N, et al. Anti-neuronal autoantibodies in both drug responsive and resistant focal seizures with unknown cause. Epilepsy Res. 2017;135:131–6.CrossRefPubMed Gozubatik-Celik G, Ozkara C, Ulusoy C, Gunduz A, Delil S, Yeni N, et al. Anti-neuronal autoantibodies in both drug responsive and resistant focal seizures with unknown cause. Epilepsy Res. 2017;135:131–6.CrossRefPubMed
19.
Zurück zum Zitat Malter MP, Frisch C, Zeitler H, Surges R, Urbach H, Helmstaedter C, et al. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure. 2015;30:57–63.CrossRefPubMed Malter MP, Frisch C, Zeitler H, Surges R, Urbach H, Helmstaedter C, et al. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure. 2015;30:57–63.CrossRefPubMed
20.
Zurück zum Zitat von Podewils F, Suesse M, Geithner J, Gaida B, Wang ZI, Lange J, et al. Prevalence and outcome of late-onset seizures due to autoimmune etiology: A prospective observational population-based cohort study. Epilepsia. 2017;58:1542–50.CrossRef von Podewils F, Suesse M, Geithner J, Gaida B, Wang ZI, Lange J, et al. Prevalence and outcome of late-onset seizures due to autoimmune etiology: A prospective observational population-based cohort study. Epilepsia. 2017;58:1542–50.CrossRef
21.
Zurück zum Zitat Khawaja AM, Vines BL, Miller DW, Szaflarski JP, Amara AW. Refractory status epilepticus and glutamic acid decarboxylase antibodies in adults: presentation, treatment and outcomes. Epileptic Disord. 2016;18:34–43.CrossRefPubMed Khawaja AM, Vines BL, Miller DW, Szaflarski JP, Amara AW. Refractory status epilepticus and glutamic acid decarboxylase antibodies in adults: presentation, treatment and outcomes. Epileptic Disord. 2016;18:34–43.CrossRefPubMed
22.
Zurück zum Zitat Quek AML, Britton JW, McKeon A, So E, Lennon VA, Shin C, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012;69:582–93.CrossRefPubMedPubMedCentral Quek AML, Britton JW, McKeon A, So E, Lennon VA, Shin C, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012;69:582–93.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA, Pettingill P, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain. 2013;136:3151–62.CrossRefPubMed Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA, Pettingill P, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain. 2013;136:3151–62.CrossRefPubMed
24.
Zurück zum Zitat Carreño M, Bien CG, Asadi-Pooya AA, Sperling M, Marusic P, Elisak M, et al. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res. 2017;129:101–5.CrossRefPubMed Carreño M, Bien CG, Asadi-Pooya AA, Sperling M, Marusic P, Elisak M, et al. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res. 2017;129:101–5.CrossRefPubMed
25.
Zurück zum Zitat Baumgartner T, Pitsch J, Olaciregui-Dague K, Hoppe C, Racz A, Rüber T, et al. Seizure underreporting in LGI1 and CASPR2 antibody encephalitis. Epilepsia. 2022;63:e100–e5.CrossRefPubMed Baumgartner T, Pitsch J, Olaciregui-Dague K, Hoppe C, Racz A, Rüber T, et al. Seizure underreporting in LGI1 and CASPR2 antibody encephalitis. Epilepsia. 2022;63:e100–e5.CrossRefPubMed
26.
Zurück zum Zitat Bien CG, Schulze-Bonhage A, Deckert M, Urbach H, Helmstaedter C, Grunwald T, et al. Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy. Neurology. 2000;55:1823–8.CrossRefPubMed Bien CG, Schulze-Bonhage A, Deckert M, Urbach H, Helmstaedter C, Grunwald T, et al. Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy. Neurology. 2000;55:1823–8.CrossRefPubMed
27.
Zurück zum Zitat Bozzetti S, Rossini F, Ferrari S, Delogu R, Cantalupo G, Marchioretto F, et al. Epileptic seizures of suspected autoimmune origin: a multicentre retrospective study. J Neurol Neurosurg Psychiatry. 2020;91:1145–53.CrossRefPubMed Bozzetti S, Rossini F, Ferrari S, Delogu R, Cantalupo G, Marchioretto F, et al. Epileptic seizures of suspected autoimmune origin: a multicentre retrospective study. J Neurol Neurosurg Psychiatry. 2020;91:1145–53.CrossRefPubMed
28.
Zurück zum Zitat Chengyu L, Weixiong S, Chao C, Songyan L, Lin S, Zhong Z, et al. Clinical features and immunotherapy outcomes of anti-glutamic acid decarboxylase 65 antibody-associated neurological disorders. J Neuroimmunol. 2020;345:577289.CrossRefPubMed Chengyu L, Weixiong S, Chao C, Songyan L, Lin S, Zhong Z, et al. Clinical features and immunotherapy outcomes of anti-glutamic acid decarboxylase 65 antibody-associated neurological disorders. J Neuroimmunol. 2020;345:577289.CrossRefPubMed
29.
Zurück zum Zitat Gofshteyn JS, Yeshokumar AK, Jette N, Thakur KT, Luche N, Yozawitz E, et al. Clinical and electrographic features of persistent seizures and status epilepticus associated with anti-NMDA receptor encephalitis (anti-NMDARE). Epileptic Disord. 2020;22:739–51.CrossRefPubMed Gofshteyn JS, Yeshokumar AK, Jette N, Thakur KT, Luche N, Yozawitz E, et al. Clinical and electrographic features of persistent seizures and status epilepticus associated with anti-NMDA receptor encephalitis (anti-NMDARE). Epileptic Disord. 2020;22:739–51.CrossRefPubMed
30.
Zurück zum Zitat Goudot M, Frismand S, Hopes L, Verger A, Joubert B, Honnorat J, et al. GAD65-Ab encephalitis and subtle focal status epilepticus. Epileptic Disord. 2019;21:437–42.CrossRefPubMed Goudot M, Frismand S, Hopes L, Verger A, Joubert B, Honnorat J, et al. GAD65-Ab encephalitis and subtle focal status epilepticus. Epileptic Disord. 2019;21:437–42.CrossRefPubMed
31.
Zurück zum Zitat Hansen N, Widman G, Witt J‑A, Wagner J, Becker AJ, Elger CE, et al. Seizure control and cognitive improvement via immunotherapy in late onset epilepsy patients with paraneoplastic versus GAD65 autoantibody-associated limbic encephalitis. Epilepsy Behav. 2016;65:18–24.CrossRefPubMed Hansen N, Widman G, Witt J‑A, Wagner J, Becker AJ, Elger CE, et al. Seizure control and cognitive improvement via immunotherapy in late onset epilepsy patients with paraneoplastic versus GAD65 autoantibody-associated limbic encephalitis. Epilepsy Behav. 2016;65:18–24.CrossRefPubMed
32.
Zurück zum Zitat Honnorat J, Didelot A, Karantoni E, Ville D, Ducray F, Lambert L, et al. Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology. 2013;80:2226–32.CrossRefPubMed Honnorat J, Didelot A, Karantoni E, Ville D, Ducray F, Lambert L, et al. Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology. 2013;80:2226–32.CrossRefPubMed
33.
Zurück zum Zitat Hou R, Wu J, He D, Yan Y, Li L. Anti-N-methyl-D-aspartate receptor encephalitis associated with reactivated Epstein-Barr virus infection in pediatric patients: Three case reports. Medicine (Baltimore). 2019;98:e15726.CrossRefPubMed Hou R, Wu J, He D, Yan Y, Li L. Anti-N-methyl-D-aspartate receptor encephalitis associated with reactivated Epstein-Barr virus infection in pediatric patients: Three case reports. Medicine (Baltimore). 2019;98:e15726.CrossRefPubMed
34.
Zurück zum Zitat Jacob S, Irani SR, Rajabally YA, Grubneac A, Walters RJ, Yazaki M, et al. Hypothermia in VGKC antibody-associated limbic encephalitis. J Neurol Neurosurg Psychiatry. 2008;79:202–4.CrossRefPubMed Jacob S, Irani SR, Rajabally YA, Grubneac A, Walters RJ, Yazaki M, et al. Hypothermia in VGKC antibody-associated limbic encephalitis. J Neurol Neurosurg Psychiatry. 2008;79:202–4.CrossRefPubMed
35.
Zurück zum Zitat Lilleker JB, Jones MS, Mohanraj R. VGKC complex antibodies in epilepsy: diagnostic yield and therapeutic implications. Seizure. 2013;22:776–9.CrossRefPubMed Lilleker JB, Jones MS, Mohanraj R. VGKC complex antibodies in epilepsy: diagnostic yield and therapeutic implications. Seizure. 2013;22:776–9.CrossRefPubMed
36.
Zurück zum Zitat Liu X, Guo K, Lin J, Gong X, Li A, Zhou D, et al. Long-term seizure outcomes in patients with autoimmune encephalitis: A prospective observational registry study update. Epilepsia. 2022;63:1812–21.CrossRefPubMed Liu X, Guo K, Lin J, Gong X, Li A, Zhou D, et al. Long-term seizure outcomes in patients with autoimmune encephalitis: A prospective observational registry study update. Epilepsia. 2022;63:1812–21.CrossRefPubMed
37.
Zurück zum Zitat Sabanathan S, Abdel-Mannan O, Mankad K, Siddiqui A, Das K, Carr L, et al. Clinical features, investigations, and outcomes of pediatric limbic encephalitis: A multicenter study. Ann Clin Transl Neurol. 2022;9:67–78.CrossRefPubMedPubMedCentral Sabanathan S, Abdel-Mannan O, Mankad K, Siddiqui A, Das K, Carr L, et al. Clinical features, investigations, and outcomes of pediatric limbic encephalitis: A multicenter study. Ann Clin Transl Neurol. 2022;9:67–78.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Santoro JD, Filippakis A, Chitnis T. Ketamine use in refractory status epilepticus associated with anti-NMDA receptor antibody encephalitis. Epilepsy Behav. 2019;12:100326.CrossRef Santoro JD, Filippakis A, Chitnis T. Ketamine use in refractory status epilepticus associated with anti-NMDA receptor antibody encephalitis. Epilepsy Behav. 2019;12:100326.CrossRef
Metadaten
Titel
Anticonvulsive treatment in autoimmune encephalitis: a systematic literature review
verfasst von
Judith N. Wagner, MD, MHBA
Publikationsdatum
17.01.2023
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 1-2/2024
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-022-00998-z